Bedrijfsoverzicht
CRISPR Therapeutics AG is a gene editing company dedicated to developing gene-based medicines intended to treat serious human diseases by utilizing its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The firm operates within the healthcare sector and specifically functions in the biotechnology industry, positioning it as an entity focused on high-risk, high-reward research and development rather than mature manufacturing or distribution. As of the latest data, the company holds a market capitalization of $4.92 billion and reports trailing twelve-month revenue of $3.51 million, while the specific count of employees is not available in the current dataset. These valuation and revenue figures indicate that the market assigns significant value to the company's intellectual property and future potential, despite the current revenue stream being relatively small compared to its market cap, which suggests an investment thesis heavily reliant on future clinical milestones and commercialization of therapies.
Financiële gezondheid
The company reported trailing twelve-month revenue of $3.51 million, a net income of $-581,598,976, and an EBITDA of $-548,838,976, highlighting a substantial divergence between top-line sales and bottom-line profitability that points to a cost structure dominated by research expenses, clinical trial costs, and general administrative overheads. Free cash flow stands at $-205,623,744, indicating that the company is currently burning cash to fund its operations and development pipeline, which limits immediate financial flexibility but is typical for early-stage biotechnology firms scaling their product candidates. The gross margin is recorded at 0.0%, the operating margin is -17912.5%, and the profit margin is 0.0%; these figures collectively reflect a business model where current costs of goods sold and operating expenses far exceed gross revenue, resulting in negative operational efficiency on a per-revenue-dollar basis for the trailing period. On the balance sheet, the company holds $1.98 billion in cash against $206.75 million in debt, supported by a debt-to-equity ratio of 10.76, which suggests a leveraged capital structure where debt obligations are significant relative to shareholders' equity, yet the massive cash reserve provides a substantial buffer against repayment needs. The current ratio is 13.32, a metric that indicates an extremely strong short-term liquidity position, meaning the company possesses more than thirteen dollars of current assets for every dollar of current liabilities, ensuring it can easily meet its short-term obligations. Return on equity is -30.2% and return on assets is -15.8%, metrics that reveal that management is currently generating negative returns on the capital invested, a common characteristic of growth-stage biotech companies that have not yet achieved commercial product success or positive earnings.
Waarderingsbeoordeling
The trailing twelve-month price-to-earnings ratio is not available (N/A) due to negative earnings, whereas the forward P/E stands at -12.23, a negative multiple that implies analysts do not expect positive normalized earnings in the near future based on current projections. The price-to-book ratio is 2.56, indicating that the market values the company at 2.56 times its book value, which suggests a premium pricing relative to the net asset value of the firm's equity. Alternative valuation metrics include a price-to-sales ratio of 1400.67 and an enterprise value-to-EBITDA of -5.73, figures that suggest the market is pricing the stock primarily on future growth expectations and asset potential rather than current profitability or cash generation capabilities. Regarding trading range, the 52-week high is $78.48 and the 52-week low is $33.03, placing the current share price in a specific position relative to this volatility band, though the exact current price is not explicitly stated in the provided facts, the wide spread between high and low reflects significant price instability over the past year. The stock carries a beta of 1.79, which indicates that the stock's price volatility is 79% higher than the broader market, signifying that investors should expect larger swings in share price both up and down compared to the S&P 500.
Growth & Income
Revenue growth year-over-year is -97.6%, while earnings growth is not available (N/A), illustrating a scenario where the company is not only failing to grow its top line but is actually contracting significantly in terms of reported sales, likely due to one-time expenses or a shift in revenue recognition patterns rather than a decline in underlying scientific progress. Since the company does not pay a dividend, there is no dividend yield or payout ratio to analyze for sustainability; instead, the company reinvests its remaining resources and cash reserves directly into research and development efforts rather than distributing income to shareholders. This growth and income profile is characterized by negative revenue expansion and a lack of current earnings or dividend distributions, creating a scenario where shareholder value is theoretically derived solely from capital appreciation and potential future clinical breakthroughs that could reverse the current financial trajectory.